19 May 2019 - Nayzilam allows for administration by a non-healthcare professional in patients actively seizing when and where a seizure cluster occurs.
UCB announced today that the U.S. FDA has approved a new drug application for the company’s newest anti-epileptic drug Nayzilam (midazolam) nasal spray, a benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.
Nayzilam now provides patients and caregivers with the first and only FDA-approved nasal option for treating seizure clusters.